Bevacizumab, Lyophilized powder

- Overview
  - Bevacizumab is a recombinant humanized monoclonal antibody used in cancer research. It can be used against vascular endothelial growth factor (VEGF). It has also been used for ophthalmic research to investigate ocular disease processes.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Bevacizumab can inhibit tumor growth in a few different ways including inhibiting new blood vessel growth, altering vascular function and blood flow in tumor, and regression of newly formed tumor vasculature. It inhibits antiogenesis via the inhibition of vascular endothelial growth factor A (VEGF-A). VEGF-A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially cancer.
- Properties
  - CAS Number
    
    216974-75-3
    
    Molecular Formula
    
    C6638H10160N1720O2108S44
    
    Molecular Weight
    
    149,146.82 g/mol
    
    Appearance
    
    Powder
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Bevacizumab is used in a variety of cancers including metastatic colon cancer, lung cancers, renal cancers, ovarian cancers, and breast cancer.